Induction Chemotherapy for Locally Advanced Esophageal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-19

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate mFOLFOX6 (5-Fluorouracil, Leucovorin and Oxaliplatin) chemotherapy as induction treatment prior to standard neoadjuvant chemoradiation to decrease the rate of distant recurrence among patients with locally advanced esophageal cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Induction FLOT With CROSS CRT for Esophageal Cancer

NCT04028167

Adenocarcinoma Esophagus Adenocarcinoma of the Gastroesophageal Junction

ACTIVE_NOT_RECRUITING PHASE2

Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer

NCT00193141

Esophagus Cancer

COMPLETED PHASE2

Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

NCT01561014

Adenocarcinoma of the Esophagus Adenocarcinoma of the Gastroesophageal Junction Adenocarcinoma of the Stomach +5 more

COMPLETED PHASE1

PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer

NCT02359968

Esophageal Neoplasms Gastro-esophageal Junction Cancer

COMPLETED PHASE2

Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer

NCT00861094

Esophageal Cancer

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The goal of the study is to evaluate mFOLFOX6 (5-Fluorouracil, Leucovorin and Oxaliplatin) chemotherapy as induction treatment prior to standard neoadjuvant chemoradiation to decrease the rate of distant recurrence among patients with locally advanced esophageal cancer. mFOLFOX6 is frequently used to treat metastatic esophageal cancer because of its high response rate in this setting. It has shown promising efficacy in several trials of patients with advanced esophageal cancer and it is the most commonly used combination regimen for this group of patients in the United States.

The investigators propose treating a sample of 40 patients with 3 cycles of induction mFOLFOX6 chemotherapy over six weeks followed by standard chemoradiation and surgery. The investigators hypothesize that patients who undergo induction chemotherapy with mFOLFOX6 prior to standard neoadjuvant chemoradiation and surgery will have a lower rate of distant disease recurrence compared to standard neoadjuvant chemoradiation and surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Induction Chemotherapy /Chemoradiation

mFOLFOX6 for 3 cycles - Oxaliplatin 85 mg/m2, 5-fluorouracil 2400mg/m2/46 hours, 5-fluorouracil bolus 400mg/m2 and leucovorin 400 mg/m2, then chemoradiation for 5 cycles - Carboplatin AUC 2mg/mL/min, Paclitaxel 50 mg/m2 and radiation therapy.

Group Type EXPERIMENTAL

mFOLFOX6

Intervention Type DRUG

Induction Chemotherapy

Chemoradiation

Intervention Type COMBINATION_PRODUCT

Chemoradiation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mFOLFOX6

Induction Chemotherapy

Intervention Type DRUG

Chemoradiation

Intervention Type COMBINATION_PRODUCT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Oxaliplatin Leucovorin 5-FU Carboplatin Paclitaxel External Beam Radiation Therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Must have histologically proven adenocarcinoma, squamous cell carcinoma or undifferentiated carcinoma of the esophagus, GE junction and/or gastric cardia.
2. Must have potentially resectable disease.
3. Must have ECOG performance status 0 or 1.
4. Must have adequate organ function as defined by the following criteria:

* ANC ≥ 1,500/mm3
* Platelet count ≥ 100,000/mm3
* Creatinine (Cr) ≤ 1.5 mg and/or creatinine clearance ≥ 60cc/min.
* Total bilirubin must be ≤ 1.5 x ULN unless the patient has a chronic grade 1 bilirubin elevation due to Gilbert's disease or similar syndrome due to slow conjugation of bilirubin.
* Alkaline phosphatase must be ≤ 2 x ULN.
* AST \& ALT must be ≤ 3 x ULN.
5. Men and women of reproductive potential must agree to use an effective contraception method
6. Must be willing and able to provide written informed consent
7. Must be ≥ 18 years or older

Exclusion Criteria

1. Prior chemotherapy, thoracic radiotherapy or prior surgical resection for an esophageal tumor.
2. Known distant metastases.
3. Patients with prior malignancies are eligible if they have been disease-free for \> 5 years and are deemed by their physician to be at low risk for recurrence. Patients with squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, or carcinoma in situ of the colon or rectum that have been effectively treated are eligible, even if these conditions were diagnosed within 5 years prior to randomization.
4. Known ≥ grade 2 neuropathy.
5. Known non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude any of the study therapy drugs.
6. Known psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude them from meeting the study requirements.
7. Women who are pregnant or nursing.
8. Women and men of reproductive potential who are expecting to conceive or father children.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No